Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - Probiodrug

October 24, 2014
LSP’S PORTFOLIO COMPANY PROBIODRUG LISTED ON EURONEXT AMSTERDAM
It is with great pleasure that today, LSP – the specialist European healthcare investment firm – announces that its portfolio company Probiodrug successfully completed its initial public offering (IPO), which was launched on 10 October 2014. More

June 17, 2010
Probiodrug expands scientific advisory board by appointing Prof Dr Lennart Mucke
Probiodrug, a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer's disease, today announced the appointment of Prof Dr Lennart Mucke to the Company's Scientific Advisory Board. More

June 16, 2010
Probiodrug obtains additional US patent for the inhibition of the enzyme glutaminyl cyclase (QC)
Probiodrug obtains additional US patent for the inhibition of the enzyme glutaminyl cyclase (QC) to treat CNS diseases More

November 2, 2009
Probiodrug closes Series B financing round exceeding EUR 36 million
Company wins BB Biotech and Edmond de Rothschild Investment Partners as co - lead investors, joined by LSP Life Science Partners , Biogen Idec New Ventures and existing investors. More

December 10, 2008
US PTO granting Probiodrug a further medical use patent for the inhibition of the enzyme QC
US PTO granting Probiodrug a further medical use patent for the inhibition of the enzyme Glutaminyl Cyclase (QC) More

September 29, 2008
Nature Medicine publication elucidating Probiodrug´s new treatment paradigm for Alzheimer’s disease
Probiodrug AG, a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, today announced the publication of in vivo data in Nature Medicine supporting the finding that inhibition of the enzyme Glutam(in)yl Cyclase can be considered as a potentially causative new treatment of neurodegeneration in Alzheimer’s Disease. More

August 14, 2008
Probiodrug to present potential new treatment for Alzheimer’s disease
Update on Novel QC inhibitors at the American Chemical Society 236th National Meeting, 2008 More

July 7, 2008
Probiodrug to present novel causative treatment approach for alzheimer’s disease
QC inhibition to be discussed at Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) 2008 More

June 23, 2008
Probiodrug receives research grant of €1.9 million
Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, announced today that the company has received a grant of €1.9 million from the public research funding program “KMU innovativ: Biotechnology-BioChance” More

Data


26,129
Tech investments
From our Online Data Service
16,883
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12N/AKnowledge management
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.